Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.

Also called NCT04373707

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,000 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04373707
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04373707. Randomized; single masking; primary purpose prevention. Start 2020-05-13 (actual); primary completion 2021-04-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
Acronym
COVI-DOSE
Condition
COVID
Condition
Thrombosis
Intervention (Drug)
Enoxaparin
Intervention (Drug)
Enoxaparin
Lead sponsor
Central Hospital, Nancy, France (class: other)
Collaborator
Ministry of Health, France (class: other government)
Collaborator
Grand Est Region (class: not stated)
Collaborator
University Hospital of Saint-Etienne (class: other)

Record details

Record id
cardio:ct-nct04373707
Content hash
76aabd02a723d0c3443782690867677f0fe548c00702dc87a8a49b58e947a0fc